Tutorials
Incyte Corp logo

Incyte Corp

$ 73.19 +1.025 (+1.42%) 02:35 PM EST
P/E:
17.21
P/B:
3.96
Market Cap:
$ 16.27B
Enterprise V:
$ 13.51B
Volume:
782.60K
Avg Vol (2M):
1.56M
Also Trade In:
Volume:
782.60K
Market Cap $:
16.27B
PE Ratio:
17.21
Avg Vol (2-Month):
1.56M
Enterprise Value $:
13.51B
PB Ratio:
3.96
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Incyte Corp
NAICS : 541714 SIC : 8731
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Financials (Next Earnings Date:2022-11-02 Est.)

INCY's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:INCY

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 3,320.472
EPS (TTM) ($) 4.25
Beta 0.63
Volatility % 24.52
14-Day RSI 32.59
14-Day ATR ($) 2.16842
20-Day SMA ($) 78.5575
12-1 Month Momentum % 3.03
52-Week Range ($) 61.91 - 84.86
Shares Outstanding (Mil) 222.43

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Incyte Corp Filings

Document Form Filing Date
No Filing Data

Headlines

See More